EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

The Prognostic Value of Circulating Tumor DNA for Clinical Outcomes in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis

Do Tung Dac iD, Hirokazu Tanaka iD, Akiyoshi Takami iD, Jorge Luis Espinoza iD

International Journal of Molecular Sciences · 04.06.2026 · 27 (11) · 5076

DOI: 10.3390/ijms27115076 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.06.2026. Verfasst von Do Tung Dac und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health Sciences, Kanazawa University, Kanazawa 9200942, Ishikawa, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Circulating Tumor DNA, Hematologic Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapse remains the leading cause of treatment failure following hematopoietic cell transplantation (HCT) for hematologic malignancies. Circulating tumor DNA (ctDNA) has emerged as a promising minimally invasive biomarker for measurable residual disease (MRD) assessment and early relapse detection; however, the prognostic significance of ctDNA in the post-transplant setting has not been comprehensively synthesized. We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines and registered the protocol in PROSPERO (CRD420261392100). PubMed, Embase, Web of Science, EBSCO, Cochrane CENTRAL, and supplementary sources were searched through November 2025. Eligible studies evaluated tumor-specific ctDNA or tumor-informed/tumor-associated cfDNA in patients undergoing allogeneic or autologous HCT for hematologic malignancies. Random-effects meta-analyses were performed for relapse/progression, overall survival (OS), and relapse-free/progression-free survival (RFS/PFS). Studies evaluating total cfDNA quantity, methylation-based cfDNA profiling, cfRNA, or chimerism-only monitoring were synthesized narratively. Ten observational cohort studies comprising 883 patients met inclusion criteria. Across acute leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes, ctDNA/cfDNA positivity was consistently associated with adverse outcomes. The pooled hazard ratio (HR) for relapse or disease progression was 12.57 (95% CI: 4.59–34.46; p < 0.001), while pooled HRs were 7.45 (95% CI: 4.11–13.48; p < 0.001) for OS and 4.46 (95% CI: 2.22–8.97; p < 0.001) for RFS/PFS. Although statistical heterogeneity was low, interpretation was limited by the relatively small number of studies contributing to each pooled endpoint. Narrative evidence additionally suggested that broader circulating nucleic acid approaches may provide complementary information regarding graft-versus-host disease, infection, and other post-transplant complications. Tumor-specific ctDNA positivity is consistently associated with increased relapse risk and inferior survival outcomes following HCT. These findings support further investigation of ctDNA-based MRD monitoring as a promising non-invasive biomarker for post-transplant molecular surveillance and risk stratification. However, prospective multicenter validation studies, assay standardization, and ctDNA-guided interventional trials remain necessary before routine clinical implementation can be recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCirculating Tumor DNAHematologic NeoplasmsBiomarkers, TumorHumansPrognosisNeoplasm, ResidualTreatment Outcome

Stichwörter der Autor:innen

MRDctDNAhematopoietic cell transplantationliquid biopsymeta-analysisminimal residual diseaserelapsesurvival

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Faculty of Health Sciences, Kanazawa University, Kanazawa 9200942, Ishikawa, Japan.
  • Department of Hematology, Faculty of Medicine, Kindai University, Osaka-Sayama 5898511, Osaka, Japan.
  • Department of Hematology, Faculty of Medicine, Aichi Medical University, Nagakute 4801195, Aichi, Japan.

ORCID-Profile: Do Tung Dac, Hirokazu Tanaka, Akiyoshi Takami, Jorge Luis Espinoza

Zitieren

APA

Dac, D. T., Tanaka, H., Takami, A., & Espinoza, J. L. (2026). The Prognostic Value of Circulating Tumor DNA for Clinical Outcomes in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 27(11), 5076. https://doi.org/10.3390/ijms27115076

Vancouver

Dac DT, Tanaka H, Takami A, Espinoza JL. The Prognostic Value of Circulating Tumor DNA for Clinical Outcomes in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2026;27(11):5076. doi:10.3390/ijms27115076

BibTeX
@article{Dac2026,
  author = {Dac, Do Tung and Tanaka, Hirokazu and Takami, Akiyoshi and Espinoza, Jorge Luis},
  title = {The Prognostic Value of Circulating Tumor DNA for Clinical Outcomes in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {5076},
  doi = {10.3390/ijms27115076}
}
Kostenlos starten →